secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001104659-25-072529
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.
- Post-split trading begins August 5, 2025 under ticker ACXP; new CUSIP 00510M 203.
- Outstanding shares reduced from ~30.8M to ~1.5M; authorized shares unchanged.
- Fractional shares paid in cash based on August 1, 2025 closing price.
- Split approved by stockholders at July 17, 2025 annual meeting; intended to regain Nasdaq minimum bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/0001104659-25-072529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/tm2521773d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer